Menin Protein and Brain Aging

Table of Contents

1. Overview
2. The MEN1 Gene and the Menin Protein
3. Classical Endocrinology — MEN1 Syndrome
4. The 2023 Brain Discovery — Hypothalamic Menin and D-Serine
5. D-Serine, NMDA Receptor Co-Agonism, and Cognition
6. Menin in Microglia and Neuroinflammation
7. Menin Restoration Strategies
8. Translational Status — Where the Evidence Actually Is
9. Practical Implications Today
10. References
11. Connections

Overview

Menin is a 610-amino-acid scaffold protein encoded by the MEN1 gene on chromosome 11q13. For nearly three decades after its 1997 identification, menin was studied almost exclusively as a tumor suppressor responsible for multiple endocrine neoplasia type 1 (MEN1) syndrome — an inherited condition characterized by tumors of the parathyroid glands, pancreatic islets, and anterior pituitary. The protein had a clear endocrine-tumor identity and a relatively small but dedicated research community working on its molecular biology and on small-molecule menin–MLL inhibitors as targeted leukemia therapies.

That picture began to shift around 2021–2023, when a series of papers from the Cai laboratory and collaborators reported that menin expression in a specific population of hypothalamic neurons declines markedly with age in mice, and that restoring menin in that brain region partially reverses several systemic features of aging — including impairments in cognition, body composition, glucose handling, and skin integrity. The proposed mechanism centered on D-serine, a co-agonist at the NMDA glutamate receptor whose production is supported by hypothalamic menin signaling. According to this hypothesis, hypothalamic menin loss leads to reduced D-serine availability, which weakens NMDA-receptor function in distant brain regions involved in learning and memory and contributes to age-related cognitive decline.

The hypothalamic-menin story is genuinely exciting because it links three previously separate domains: a well-characterized endocrine tumor-suppressor protein, a well-characterized neuromodulator (D-serine), and a high-priority but mechanistically vague clinical problem (cognitive aging). It also offers a relatively concrete intervention concept: D-serine itself is an inexpensive amino acid that has been used in human trials at multi-gram daily doses for schizophrenia and cognitive endpoints. The translational distance between mouse hypothalamic neurons and a clinically useful intervention is still substantial, but the conceptual pathway is one of the more tractable in modern brain-aging research.

This page summarizes what menin is, what we have learned about its newly described role in brain aging, where the evidence is firm, and where it is preliminary. The goal is to help readers interpret news coverage of "menin restoration" claims without either dismissing the underlying biology or overstating how close it is to a clinical product.

Back to Table of Contents

The MEN1 Gene and the Menin Protein

The MEN1 gene was cloned in 1997 by Chandrasekharappa and colleagues working in the laboratory of Francis Collins at the National Human Genome Research Institute. Positional cloning of the responsible gene on 11q13 had been a multi-year effort across several international groups; the 1997 Science paper identified a 10-exon gene encoding a 610-amino-acid protein that was named menin. The gene is broadly expressed across tissues, but its loss-of-function consequences are most visible in endocrine cells, where it functions as a tumor suppressor in a classical two-hit Knudson sense: a germline loss-of-function allele predisposes to tumors that arise after somatic loss of the remaining wild-type allele.

At the molecular level, menin is a nuclear scaffold protein. It has no enzymatic activity of its own. Instead, it serves as an assembly platform that brings together other functional proteins into multiprotein complexes. The best-characterized of these is its participation in the MLL/KMT2A histone methyltransferase complex, which deposits H3K4 trimethylation marks at the promoters of target genes. By holding MLL near specific chromatin sites, menin contributes to the gene-expression programs that those marks support — including, importantly, expression of the cyclin-dependent kinase inhibitors p27 (CDKN1B) and p18 (CDKN2C), which restrain endocrine-cell proliferation.

Menin also interacts directly with the tumor suppressor p53 and with several transcription factors involved in TGF-beta and Wnt signaling. Loss of menin destabilizes p53 activity, removes the p27/p18 brakes on the cell cycle, and disinhibits Wnt-driven proliferation in endocrine progenitor cells. The net effect in pancreatic islet beta cells, parathyroid chief cells, and pituitary anterior-lobe cells is unchecked clonal expansion — the cellular basis of MEN1 syndrome.

Outside the MLL complex, menin participates in DNA damage response pathways and in regulation of the JunD transcription factor. JunD is unusual among the AP-1 family in being preferentially anti-proliferative; menin enhances JunD's anti-proliferative effect, so loss of menin removes this brake as well. These interactions are part of what makes menin a multi-function scaffold rather than a single-pathway protein, and they help explain why menin loss produces phenotypes ranging from endocrine neoplasia to leukemia to, now apparently, hypothalamic dysfunction.

Back to Table of Contents

Classical Endocrinology — MEN1 Syndrome

Multiple endocrine neoplasia type 1, also called Wermer syndrome, is the inherited disorder for which the MEN1 gene is named. It affects approximately 1 in 30,000 people and is inherited as an autosomal dominant condition with high penetrance: by age 50, more than 90 percent of carriers show clinical or biochemical evidence of disease. The classical triad is tumors of the parathyroid glands, the endocrine pancreas, and the anterior pituitary. Other manifestations include adrenocortical tumors, foregut carcinoid tumors, lipomas, angiofibromas, and collagenomas.

Primary hyperparathyroidism is usually the earliest manifestation, often presenting in the second or third decade of life with multi-gland parathyroid hyperplasia rather than the single adenoma typical of sporadic disease. Surgical management is more complex for the same reason. Pancreatic neuroendocrine tumors in MEN1 are frequently multiple and small; they include functional gastrinomas (causing Zollinger-Ellison syndrome), insulinomas, and a substantial fraction of non-functional but still potentially metastatic lesions. Pituitary tumors are most often prolactinomas, with growth-hormone- and ACTH-secreting tumors representing smaller subsets.

From a brain-aging perspective, the most important lesson of MEN1 syndrome is that menin loss in adult endocrine cells produces clonal expansion and tumorigenesis. This means that any "menin restoration" intervention aimed at the central nervous system must be highly targeted — ideally to specific hypothalamic neurons — rather than systemic. Globally raising menin in all tissues is biologically implausible as a longevity strategy because the tumor-suppressor function is already saturated in most adult cells, and globally lowering menin would, in some tissue compartments, be frankly oncogenic.

The flip side of the same observation is that menin loss is therapeutically useful in a different cellular context: certain MLL-rearranged leukemias depend on the menin–MLL interaction for their abnormal gene-expression programs. Disrupting this interaction with small-molecule menin inhibitors (revumenib was approved by the FDA in late 2024 for relapsed/refractory KMT2A-rearranged acute leukemia) starves the leukemic cells of the transcriptional support they need. This pharmacology cuts in the opposite direction of the brain-aging hypothesis, which would want more menin function in hypothalamic neurons. Both can be true at the same time, in different tissue compartments, because menin's function is determined by the partner proteins available to it in each cell type.

Back to Table of Contents

The 2023 Brain Discovery — Hypothalamic Menin and D-Serine

The reframing of menin as a brain-aging protein emerged from work in the laboratory of Dongsheng Cai at the Albert Einstein College of Medicine, with collaborators in China and the United States. The Cai laboratory has spent more than a decade investigating the hypothalamus as a regulator of systemic aging, building on earlier observations that hypothalamic inflammation accelerates aging phenotypes and that hypothalamic stem cells and microRNAs can influence lifespan in mice.

In a series of papers culminating in a 2023 report, the group described a population of menin-expressing neurons in the ventromedial and arcuate regions of the mouse hypothalamus whose menin protein levels decline progressively with age. They reported that experimentally lowering menin in those neurons in young mice produced phenotypes that resembled accelerated aging — including impairments in spatial memory, alterations in body composition, increased systemic low-grade inflammation, and changes in skin and bone. Conversely, restoring menin in those neurons in old mice using viral-vector gene delivery improved several of these measures, including performance on memory tasks.

The proposed mechanism centered on the amino acid D-serine. Hypothalamic menin loss was shown to lower the expression of enzymes involved in D-serine synthesis and turnover, with a net reduction in central D-serine availability. Because D-serine is a key co-agonist at NMDA-type glutamate receptors throughout the brain — including in hippocampus and cortex — reduced D-serine availability impairs NMDA-receptor function and the synaptic plasticity it supports. Restoring menin in the hypothalamus, or supplementing D-serine directly in the drinking water of aged mice, partially reversed the cognitive deficits in their reported models.

This work has been received with cautious enthusiasm by the brain-aging field. The strengths are the use of orthogonal interventions (genetic, viral, and dietary) that converge on the same readouts, and the identification of a specific molecule (D-serine) that is already known to be biologically active at NMDA receptors and that drops with age in human cerebrospinal fluid. The limitations — appropriately acknowledged by the authors and by commentators — are that the work is in mice, that the magnitude of cognitive improvement is modest, and that hypothalamic-to-hippocampus signaling pathways for a freely diffusing amino acid are still being mapped.

Back to Table of Contents

D-Serine, NMDA Receptor Co-Agonism, and Cognition

The mammalian central nervous system contains substantial concentrations of D-serine, the right-handed stereoisomer of the dietary amino acid L-serine. D-serine is synthesized in the brain from L-serine by the enzyme serine racemase, and it is degraded by D-amino acid oxidase. Once thought to be a microbial-only metabolite, D-serine is now recognized as a major physiological co-agonist at the NMDA glutamate receptor, binding at the glycine-modulatory site and required — together with glutamate — for NMDA-receptor channel opening.

NMDA receptors are central to most current models of learning and memory. They permit calcium entry into postsynaptic neurons when both glutamate and a co-agonist (glycine or D-serine) are present, triggering downstream signaling cascades that strengthen synapses (long-term potentiation, LTP) or weaken them (long-term depression, LTD). The dependence on a co-agonist makes NMDA-receptor function exquisitely sensitive to the concentration of available D-serine or glycine, and chronic reductions in either reduce the plasticity ceiling of the network.

D-serine levels in cerebrospinal fluid and in postmortem brain tissue decline with age in humans, and several lines of evidence link reduced D-serine availability to cognitive aging and to the cognitive features of schizophrenia. Clinical trials of D-serine supplementation in schizophrenia, typically at doses of 30 to 60 mg per kilogram per day (which translates to roughly 2 to 4 grams daily for an average adult), have shown modest improvements on negative symptoms and cognitive measures in some but not all studies. The amino acid is generally well tolerated at these doses in published trials, with the main concern being theoretical: at supra-physiological exposure, D-amino acid oxidase activity in the kidney could generate hydrogen peroxide and cause renal damage, an effect documented in rats at very high doses.

For the menin hypothesis, the practical importance of D-serine is that it provides a downstream, pharmacologically accessible target. Even if direct manipulation of hypothalamic menin in the human brain remains years away, D-serine itself is an off-the-shelf molecule, and modest reductions in its central availability with age are a measurable target. Whether D-serine supplementation produces cognitive benefits in non-schizophrenic older adults at risk of cognitive decline is a question that would benefit from dedicated, adequately powered trials.

Back to Table of Contents

Menin in Microglia and Neuroinflammation

Beyond its role in hypothalamic neurons, menin participates in epigenetic programming of immune cells, including microglia — the central nervous system's resident innate immune population. Menin's partnership with the MLL/KMT2A H3K4 methyltransferase complex deposits activating chromatin marks at the promoters of specific inflammatory and metabolic genes, helping to define the transcriptional state of myeloid cells.

During aging, microglia drift from a homeostatic, surveillance-oriented state toward a "primed" or "senescent" state characterized by increased baseline expression of inflammatory cytokines, reduced phagocytic clearance of debris, and exaggerated responses to secondary insults. This drift is one component of the broader concept of inflammaging — the chronic, low-grade, sterile inflammation that accompanies organismal aging across multiple tissues. In the brain, primed microglia are implicated in the pathophysiology of Alzheimer's disease, Parkinson's disease, vascular cognitive impairment, and post-operative or post-illness delirium.

The intersection with menin is conceptually rich but mechanistically still being mapped. The same MLL/menin axis that controls developmental gene expression in endocrine progenitors also tunes inflammatory gene expression in mature myeloid cells. Whether age-related changes in microglial menin contribute to microglial priming, and whether the proposed hypothalamic-menin decline alters peripheral signals that feed into microglial state, are open questions that the field has begun to investigate. Reviews in 2023 and 2024 have framed the menin–MLL axis as one of several epigenetic nodes that could plausibly integrate metabolic, hormonal, and inflammatory inputs in brain aging.

The practical takeaway for readers is that "menin in brain aging" is unlikely to be a single, unitary mechanism. The hypothalamic-D-serine story is the cleanest current narrative, but it sits inside a larger landscape in which menin contributes to gene-expression programs in multiple cell types, including the immune cells whose drift over time shapes the brain's inflammatory tone.

Back to Table of Contents

Menin Restoration Strategies

If the hypothalamic-menin hypothesis is broadly correct, several intervention strategies become conceptually plausible. None is currently a clinical product, and all sit at different distances from human application.

• D-serine supplementation — The most accessible downstream rescue. D-serine is an inexpensive amino acid that has been used in human trials at multi-gram daily doses for schizophrenia. The proposed brain-aging dose would likely fall in a similar or somewhat lower range, but dedicated trials in non-schizophrenic older adults have not been completed.
• NMDA-receptor modulators with co-agonist activity — D-cycloserine is a partial agonist at the NMDA glycine site and has been used at low doses (typically 50–100 mg) in trials of cognitive enhancement in extinction learning and exposure therapy. Sub-anesthetic ketamine, which acts as an NMDA antagonist, has been studied for depression and post-traumatic stress disorder; its relationship to the menin/D-serine pathway is mechanistically inverse but clinically informative.
• Gene-therapy concepts — The mouse studies that motivated the hypothesis used adeno-associated virus (AAV) vectors delivered into the hypothalamus to raise menin expression in specific neurons. Direct hypothalamic AAV delivery in humans is technically feasible for other indications but is invasive and would face substantial safety review, particularly given the tumor-suppressor role of menin in non-target tissues.
• Lifestyle inputs to hypothalamic stress — The Cai laboratory has previously linked hypothalamic inflammation and stress to aging phenotypes, and downstream this connects to interventions that reduce systemic inflammatory load: caloric moderation, regular aerobic and resistance exercise, adequate sleep, glycemic control, and avoidance of chronic alcohol exposure. None of these is specific to menin, but each may slow the hypothalamic-stress trajectory that the menin story sits inside.
• mTOR and NAD+ context — Rapamycin (an mTOR inhibitor) and NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) are the two most-studied small molecules in mainstream longevity research. Their relationship to the menin pathway is not directly established but is biologically plausible: mTOR signaling controls protein-synthesis programs that include scaffold proteins like menin, and NAD+ availability constrains the activity of sirtuins and PARPs that participate in the same chromatin-modification universe.

The conservative read is that D-serine supplementation is the closest-to-actionable concept, and even there the clinical data outside schizophrenia are thin. The other strategies are research-stage and should not be presented as products.

Back to Table of Contents

Translational Status — Where the Evidence Actually Is

It is worth being explicit about the evidence hierarchy for this topic, because it sits at a stage of the research cycle where overstatement is easy and corrosive.

• Robust: menin is a real scaffold protein, encoded by MEN1, and a bona fide tumor suppressor in endocrine tissue. The menin–MLL interaction is a validated drug target in MLL-rearranged leukemia. D-serine is a real NMDA co-agonist whose levels decline with age in human cerebrospinal fluid. NMDA-receptor function is central to learning and memory and is impaired in cognitive aging.
• Reasonably supported but still preclinical: menin expression in hypothalamic neurons declines with age in mice; reducing hypothalamic menin in young mice produces phenotypes resembling accelerated aging; restoring menin or supplementing D-serine partially reverses some of these phenotypes in mouse models, with effects on memory tasks, body composition, and tissue integrity.
• Hypothesis-level: the same hypothalamic-menin decline drives meaningful systemic and cognitive aging in humans; restoring central menin function or D-serine availability will produce clinically detectable cognitive benefit in older adults; menin-based interventions can be made safe in humans given the tumor-suppressor concerns.
• Not established: any consumer supplement product currently being marketed as a "menin restoration" intervention has clinical evidence of efficacy or has been demonstrated to raise central menin levels in humans. Several products in this category exist; readers should treat their claims with skepticism until peer-reviewed human data appear.

This division matters because the popular-science framing has moved faster than the human trial evidence. The mouse studies are genuinely interesting and the underlying biology is plausible, but the translational distance is real and should not be papered over.

Back to Table of Contents

Practical Implications Today

For an interested reader who wants to act on this body of work without buying speculative products, the most defensible posture is to manage the interventions we already know support brain aging and to wait for human menin-pathway trial data before adding anything new. The same broad set of inputs shows up across the menin literature, the hypothalamic-aging literature, and the longevity literature more generally:

• Sleep and glymphatic clearance — The brain's clearance system for protein aggregates and metabolic waste operates predominantly during sleep, particularly deep slow-wave sleep. Chronic sleep restriction or fragmentation reduces clearance and accelerates the accumulation of aggregation-prone proteins implicated in dementia. Seven to nine hours of regularized sleep is one of the highest-yield, lowest-cost interventions in brain aging.
• Exercise and hypothalamic effects — Aerobic and resistance exercise alter hypothalamic inflammatory signaling, improve insulin sensitivity (which itself is a hypothalamic input), and increase brain-derived neurotrophic factor (BDNF) in regions involved in learning and memory. The exercise literature is one of the few in brain aging where the human evidence is comparable in quality to the mouse evidence.
• mTOR sanity — Chronic over-nutrition and persistently elevated insulin and IGF-1 signaling drive mTOR activity beyond what evolved environments selected for. Time-restricted eating windows, avoidance of late-evening meals, and resistance to chronic snacking probably help to keep this signaling axis closer to its physiological set point. Pharmacological mTOR inhibition with rapamycin is studied in formal clinical trials but is not a self-administered intervention.
• NAD+ context — NAD+ precursors are widely available as supplements (nicotinamide riboside, nicotinamide mononucleotide), and human data on their cognitive and metabolic effects are still being accumulated. They are not menin pathway interventions but they sit in the same metabolic-epigenetic neighborhood and are the subject of ongoing research.
• Glycemic and metabolic control — Insulin resistance, type 2 diabetes, and hypertension are among the strongest modifiable risk factors for cognitive decline and dementia. Improvements in these systemic markers feed back to hypothalamic function and to the broader inflammatory tone of the brain.
• Cautious skepticism of "menin restoration" supplement claims — Be wary of products marketed with mouse-study citations as if they were human-trial data. The mouse data are interesting; they are not yet the basis for a clinical product, and any product claiming to "raise menin levels" in humans should be evaluated against the absence of validated human assays for central menin status.

The menin and D-serine work is one of the most interesting threads in current brain-aging research because it offers a concrete molecular target downstream of a poorly understood phenomenon. It is also early enough that the most useful posture for non-researchers is to follow the evidence as it accumulates rather than to act prematurely.

Back to Table of Contents

References

1. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404-407. PMID: 9103196. DOI: 10.1126/science.276.5311.404.
2. Hughes CM, Rozenblatt-Rosen O, Milne TA, et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Molecular Cell. 2004;13(4):587-597. PMID: 14992727. DOI: 10.1016/S1097-2765(04)00081-4.
3. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207-218. PMID: 16239140. DOI: 10.1016/j.cell.2005.09.025.
4. Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends in Biochemical Sciences. 2013;38(8):394-402. PMID: 23850066. DOI: 10.1016/j.tibs.2013.05.005.
5. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Journal of Clinical Endocrinology & Metabolism. 2012;97(9):2990-3011. PMID: 22723327. DOI: 10.1210/jc.2012-1230.
6. Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proceedings of the National Academy of Sciences. 2000;97(9):4926-4931. PMID: 10781100. DOI: 10.1073/pnas.97.9.4926.
7. Wolosker H, Balu DT, Coyle JT. The rise and fall of the d-serine-mediated gliotransmission hypothesis. Trends in Neurosciences. 2016;39(11):712-721. PMID: 27742076. DOI: 10.1016/j.tins.2016.09.007.
8. Billard JM. D-serine in the aging hippocampus. Journal of Pharmaceutical and Biomedical Analysis. 2015;116:18-24. PMID: 25933793. DOI: 10.1016/j.jpba.2015.04.013.
9. Zhang G, Li J, Purkayastha S, et al. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature. 2013;497(7448):211-216. PMID: 23636330. DOI: 10.1038/nature12143.
10. Zhang Y, Kim MS, Jia B, et al. Hypothalamic stem cells control ageing speed partly through exosomal miRNAs. Nature. 2017;548(7665):52-57. PMID: 28746310. DOI: 10.1038/nature23282.
11. Issa NT, Wathieu H, Ojo A, Byers SW, Dakshanamurthy S. Drug Metabolism in Preclinical Drug Development — menin–MLL inhibitors. Current Opinion in Chemical Biology. 2020;56:60-70. PMID: 32007703. DOI: 10.1016/j.cbpa.2019.12.005.
12. Avanesov AS, Ma S, Pierce KA, et al. Age- and diet-associated metabolome remodeling characterizes the aging process driven by damage accumulation. eLife. 2014;3:e02077. PMID: 24843015. DOI: 10.7554/eLife.02077.

External Authoritative Resources

• GeneReviews — Multiple Endocrine Neoplasia Type 1
• NINDS — Dementia and Cognitive Aging
• PubMed — menin hypothalamus aging (live search)
• PubMed — D-serine cognition aging (live search)

Back to Table of Contents

Connections

• Brain Aging Overview
• Rapamycin
• Longevity Protocols
• NAD+ / NMN
• Gut-Brain Axis
• Alzheimer's Disease
• Parkinson's Disease
• Cancer (MEN1 syndrome context)
• Vitamin B12
• Vitamin D3
• Magnesium
• Berberine

Back to Table of Contents

×